A new survey by Petplan has given an insight into how veterinary nurses regard their job.
The survey, conducted at BVNA Congress, found that 73% of nurses feel that clients do not have a sufficient understanding of their role in practice.
Louisa Baker, the 2008 Petplan Vet Nurse of the Year, said: "Clients are often not aware of the skills required to be a vet nurse. Most clients believe we just handle the animals whereas we are often involved with surgical activities such as stitching and preparing drips."
Arguably, if pet owners under-appreciate the role of the nurse in practice, then they might also be expected to place a lower financial value on the care they provide. If that is the case, then it makes a lot of sense for vets and practice owners to find novel ways of communicating the breadth of work that nurses do, and its importance, to clients.
Other findings included 40% of nurses agreeing that direct contact with animals, such as caring for them through recovery, is the best part of the job. 54% told Petplan that they find the job extremely rewarding.
Nearly all nurses (99%) said that they value training and CPD to further their careers.
To support this desire to learn, Petplan has launched its Petplan Insurance Advisor training scheme. Already, over 500 nurses have completed one of the scheme's CPD qualifying modules.
The scheme enables the development of individual skills such as the ability to sell products and gain confidence with clients. Available online, vet nurses can participate in the scheme at work or at home. Visit http://www.petplanpia.co.uk/ for more information.
Ceva Animal Health has added a new CPD module to its Cardio Academy website which focuses on common heart diseases in cats.
The 20 minute online seminar is hosted by Virginia Luis-Fuentes, Professor of Veterinary Cardiology at the Royal Veterinary College. After viewing the module, you can claim a CPD certificate by answering questions relating to the session.
Fraser Broadfoot MRCVS, product manager at Ceva, said: "Cardio Academy is going from strength to strength with over 1500 UK vets registered to the site which now includes 15 hours of free on-demand cardiology CPD with leading specialists."
For more information, visit: www.cardioacademy.cevalearn.com.
Mark Colonnese, Aquarium’s Sales and Marketing Director said: "As someone who owns two dogs, the results of the survey have not come as too much of a surprise to me, but I know that some of my colleagues were pretty surprised just how important we think our pets are."
The survey showed that the feelings were even stronger among women, 71% of whom would regard a pet death as equally upsetting to that of a family member’s, compared to 55% of men.
Mark added: "Our results really highlight the sensitivity of issues surrounding a pet’s death. While this would be obvious to, for instance, a life insurance company, our survey reinforces the need for an empathetic customer journey among pet insurers. The first step of this process is ensuring a smooth, seamless process to minimise stress for newly bereaved pet parents."
For this study, researchers in Argentina, Italy, Austria and Chile, set out to evaluate the efficacy of and adverse events from the administration of ACEIs to treat preclinical MMVD in dogs, via a systematic review of published evidence conducted according to the Cochrane Handbook for Systematic Reviews of Interventions.
Certainty of evidence was assessed using the GRADE (https://gradepro.org) approach.
The main finding in relation to dogs with preclinical MMVD and cardiomegaly was backed by a high certainty of evidence. The certainty of evidence in relation to the efficacy of ACEI administration in dogs without cardiomegaly was low.
Dr Pablo Donati, corresponding author for the paper, said: “In recent times, multiple clinical trials have provided fundamental information to veterinary cardiology.
"In the era of evidence-based medicine, systematic reviews and meta-analyses have emerged as a fundamental tool for clinical decision-making by gathering, appraising and summarizing the best available evidence.
"It is the hope of the authors that this systematic review and meta-analysis helps in the decision-making process for the treatment of preclinical myxomatous mitral disease with angiotensin-converting enzyme inhibitors in dogs.”
Nicola Di Girolamo, Editor of JSAP, added: “In line with other leading journals, the JSAP is prioritizing the publication of methodologically sound systematic reviews such as this one.
"However, our readers should be aware that the findings of systematic reviews should always be considered in light of their internal validity, i.e. the quality of the included studies, and their external validity, i.e. the generalizability of the included studied to the individual patient.”
Reference
Donati, P., Tarducci, A., Zanatta, R., Verdier, N., Belerenian, G., Cordero, I., Villalta, C., Franco, J. and Tarragona, L. (2022), Angiotensin-converting enzyme inhibitors in preclinical myxomatous mitral valve disease in dogs: systematic review and meta-analysis. J Small Anim Pract. https://doi.org/10.1111/jsap.13461
The Association says it has produced the leaflet after seeing an increasing number of dogs diagnosed with clinical or subclinical infection, along with reports of its zoonotic impact.
The document outlines the most important considerations concerning B. canis including transmission, diagnosis, management, public health implications and legislative requirements.
It takes into consideration information available from relevant Government Departments.
BSAVA says the document is by no means exhaustive but is intended to provide useful information and signpost to further resources.
www.bsavalibrary.com/brucella_canis
Photo: Walker16/Wikipedia. CC BY-SA 4.0.
The RCVS said: "We understand that there are very strong opinions about the ban, and we respect the rights of individuals to make their own decisions.
"However, expressing these opinions can never justify or include the harassment and abuse of individual vets, vet nurses or their practice colleagues."
The BVA added: “The Government’s XL Bully ban is also placing additional pressure on veterinary teams who are doing their best in very challenging circumstances to help keep responsible XL Bully owners with their pets wherever possible.
"Their commitment extends to supporting clients with any decision-making around euthanasia in individual cases.
"It’s simply unacceptable for these professionals to face additional challenges through abuse, intimidation or threats.
"Such actions can have a hugely negative impact on individual vets and the wider team."
Resources:
Photo: Dlexus
The poster gives information about things like lillies, chocolate, raisins, fertilisers, weedkillers and adders.
TVM will also be running its annual social media campaign about the most common spring dangers, giving practices digital content which they can share with clients.
To get a poster for your practice, contact your local TVM territory manager or visit https://www.tvm-uk.com/pet-dangers-order-free-display-materials-for-your-practice.
Newmarket-based Test and Treat was one of three finalists, for its U-Treat test which enables vets to diagnose a UTI and get antibiotic sensitivity results in an hour.
Rachel Kirkby MRCVS, Business Development Director at Test and Treat, said: "It’s a great accolade to be recognised by such a prestigious award. The Vet Record Innovation Award celebrates new innovations that can bring about improvement and make a real difference to vets in practice – and that’s exactly what we’re aiming to do with U-Treat.”
The second finalist was the Animal Welfare Assessment Grid, developed by Public Health England (PHE), in collaboration with the University of Surrey School of Veterinary Medicine. Initially developed in zoos, rescue and research centres, there are plans now to develop it for use in small animal practice and in the farm sector.
The overall winner was PBD Biotech for Actiphage, its test for bTB and Johne's disease which gives very early detection, thereby allowing vets and farmers to prevent the spread of infection.
For more information, visit: https://bvajournals.onlinelibrary.wiley.com/doi/10.1002/vetr.267
Fort Dodge has announced that a challenge study has demonstrated the ability of Duvaxyn® IE-T Plus equine influenza vaccine to cross protect against A/equi-2/Sydney/07 (H3N8) two weeks after a two dose primary course. This strain was responsible for the financially devastating equine influenza outbreak in Australia in August 2007.
Duvaxyn IE-T Plus is an inactivated whole virus equine influenza vaccine, adjuvanted with an aqueous-based adjuvant. According to Fort Dodge, experts at a recent WHO meeting on human vaccines expressed the view that whole virus vaccines have the potential to induce a stronger and more broadly based response to circulating influenza strains than those contained in sub-unit vaccines because of the presence of the full set of virus proteins in the vaccine*.
The study, conducted by the Animal Health Trust, involved two groups of EIV seronegative horses. The first group, consisting of seven vaccinates, were given two dose of Duvaxyn IE-T Plus, 28 days apart, and challenged with A/equi-2/Sydney/07 (H3N8) virus strain 14 days after the second vaccination. The second group of unvaccinated horses was challenged at the same time. Duvaxyn IE-T Plus caused a statistically significant reduction in both clinical signs of the disease and in viral shedding.
Helen Barnes, EMEA Equine Business Manager for Fort Dodge, said: "The results of this challenge study provide reassurance for owners that horses vaccinated with Duvaxyn will be protected against circulating strains of equine influenza, including the Sydney strain which proved so damaging.
"As the benefits offered by whole virus technology are increasingly recognised, the popularity of vaccines based on this technology is re-emerging, particularly to combat a potential pandemic.
"The entire Duvaxyn range of equine vaccines, including the recently licensed Duvaxyn WNV for West Nile Virus, are based on the whole virus approach as we believe it offers a broad and consistent level of protection."
SRUC, which is the biggest provider of veterinary nursing, livestock husbandry and animal care training in Scotland, says it will offer a core veterinary programme to address existing shortages in veterinary provision, in areas such as rural veterinary practice, food production, food safety and animal and public health.
The College is first establishing a working group to progress the plans for the school. The group will be chaired by Professor Sir Pete Downes, former Principal and Vice-Chancellor of the University of Dundee.
Sir Pete will be joined by Sheila Voas, Chief Veterinary Officer for Scotland, former NFUS President Nigel Miller, SRUC Board member Jane Craigie, and Dr Kate Richards, who is a non-executive director on the SAC Commercial Board and currently the junior vice president of the RCVS, in line to become President in July.
Professor Caroline Argo, currently Dean of SRUC’s North Faculty, will lead the project for SRUC.
A report from BiGGAR Economics has found that the vet school could add £26 million GVA and 242 jobs to Scotland by 2030.
Professor Wayne Powell, Principal and Chief Executive of SRUC, said: “We are an ambitious institution with a bold vision for the future. This is a ground-breaking model to expand access to educational opportunities and broaden the range of potential students who would not ordinarily be able to attend a vet school. It will also help solve existing skills shortages across Scotland.
“We see a key role of the new vet school in sustaining primary agriculture and hence food and drink productivity, with the welfare of both livestock and companion animals at its heart. The school will produce champions for best-in-class animal welfare in support of these industries, which will help improve productivity, effectiveness, and sustainability.”
“Building on the excellent new facilities we have already announced for Aberdeen and Inverness, there is a lot of work still to be done, but we are ready to seize the opportunity.”
The university says it has implemented a range of health and safety measures to meet Government guidelines and allow for the controlled return of 150 first-year undergraduate students to its Sutton Bonington campus.
Since the latest cohort joined the university at the height of the UK lockdown, the school has delivered a programme of technology-assisted Fresher’s Week and teaching activities.
However, the return of the April cohort will enable face-to-face teaching that cannot be delivered remotely, specifically essential animal handling and health and safety skills required before students can embark on the work experience element of their course.
The practical sessions will form part of a blended approach to learning, with other lectures and tutorial support continuing to be delivered remotely to reduce the number of students in teaching buildings at any one time.
Dean of the School of Veterinary Medicine and Science Professor Gary England said: “We have missed being on campus with our students tremendously during the coronavirus lockdown and we are excited to be welcoming this cohort to Sutton Bonington in July.
“The health and safety of our students and staff has remained our top priority and has been at the heart of our planning process. Colleagues from across the university have been working intensively on the intricate detail required to ensure that adequate social distancing and hygiene measures are in place to allow this first step in a return to campus.”
Among the measures which have been introduced are:
The university says the return of its vet school cohort and the re-starting of face-to face-education at University of Nottingham Ningbo China at the end of April, where 5,000 students are now back on campus, will form the blueprint for the return of the majority of students to its UK campuses when the new academic term begins on 21 September.
The VCMS, which is administered by Nockolds Solicitors, was formally launched by the RCVS as an alternative dispute resolution service in October 2017 following a year-long trial.
The aim of the service is to resolve, by mediation, disputes between clients and veterinary practices that do not meet the threshold of serious professional misconduct that is needed for the RCVS to investigate a concern through its formal processes.
Since the service’s trial, which started in October 2016, the VCMS has given preliminary mediation advice on how to resolve a case in more than 1,700 instances with over 580 cases having gone to full mediation of which 89% have concluded with a resolution.
Eleanor Ferguson, RCVS Registrar and Director of Legal Services, said: "From the perspective of both the public and the profession, the establishment of the VCMS has been a "win-win" situation. For the public it has provided them with an additional route to solve those complaints which wouldn’t cross the threshold to progress in the concerns investigation process.
"For the profession it has provided a more appropriate format for resolving a client dispute that doesn’t involve the time, effort and formal process of an RCVS investigation for those cases that will never amount to serious professional misconduct. I think this has been demonstrated by the fact that the vast majority of the profession are willing to engage with the VCMS process, even though it is entirely voluntary.
"The VCMS has also had a positive impact on the College and its concerns investigation process, allowing us to focus greater resources on those cases that do meet our threshold of serious professional misconduct. This has had a very clear impact on the speed with which we either close cases or move them on to the next stage of consideration by the Preliminary Investigation Committee (PIC), which, again, is important to both the public and the profession."
The College says that around 90% of cases investigated at Stage 1 of the process are now either closed or referred to PIC within four months – the College’s key performance indicator at this stage. This compares to around 50% of these cases being closed or referred within four months at Stage 1 in 2016.
The College also says that in total (including both preliminary and full mediation cases), 86% of the cases dealt with by VCMS were successfully mediated and feedback from both clients and veterinary practices has been largely positive. In client feedback from the third quarter of 2018, 93% said they would use the VCMS again and 79% considered it to be fair, while the equivalent figure amongst veterinary practices was 94% and 87% respectively.
Jennie Jones, a partner at Nockolds Solicitors who heads up the VCMS, said: "It is a good sign that mediation is largely working as it should when both parties are reporting similar satisfaction rates and we pride ourselves on negotiating resolutions that are acceptable and beneficial for both the clients and the practices.
"It is great to see that our efforts are also having an impact on the RCVS concerns investigation system by allowing it to concentrate on more serious cases."
More information about the RCVS concerns investigation process, including the different stages of an investigation, can be found at www.rcvs.org.uk/concerns
Further information about the VCMS can be found on its website at www.vetmediation.co.uk or by calling 0345 040 5834.
Ceva Animal Health has launched Marboxidin chewable tablets for dogs and cats for the treatment of micro-organisms susceptible to marbofloxacin, including skin and soft tissue infections (in cats and dogs), respiratory tract infections (in dogs and cats) and urinary tract infections (in dogs).
Containing marbofloxacin as its active ingredient, Marboxidin has a taste-masking lipid coating to ensure that its bitterness is not detected. In palatability trials over 90% of dogs and 80% of cats voluntarily consumed Marboxidin chewable tablets from the hand or in food1. Ceva says that Marboxidin is also very cost-effective, with an ongoing discount using the new CevaSave rebate scheme.
Marboxidin chewable tablets are available in three tablet sizes (5mg, 20mg and 80mg).
For further details, contact your Ceva Territory Manager or telephone the customer support team on (01494) 781510.
References
Maeve Cuffe, Junior Brand Manager of large animal products, at Forte Healthcare Ltd said: “As dairy herds increase in size, routine fertility visits result in larger numbers of cows requiring prostaglandin treatment.
"Also, some vets now recommend two shots of prostaglandin instead of one in certain synchronisation protocols.
"The 25 dose presentation of Genestran is a great addition to the range, helping vets keep enough prostaglandin in stock, while minimising waste.”
Genestran 50ml is available in all veterinary wholesalers now.
Technical questions about Genestran should be sent to: vets@fortehealthcare.com
Colin graduated from the RVC in 1992 and has worked as a clinical veterinary surgeon in a variety of first opinion practices and referral centres. He trained as a veterinary anaesthetist at Bristol and Cambridge Universities before moving into the pharmaceutical industry, gaining experience in drug development and technical support, and pre- and post-marketing, at a number of companies.
Colin said: “Animalcare is introducing a number of new and innovative medicines, such as Daxocox, its weekly NSAID to reduce breakthrough pain in dogs with osteoarthritis, to the veterinary sector. This makes it an exciting environment in which to provide technical support.
“I’m looking forward to exploring how my experience can be most useful in supporting Animalcare’s expansion and, more importantly, ensuring that the company’s customers receive the guidance and advice they need to optimise the effectiveness of Animalcare’s product range in treating their patients.”
For technical support, email: technical@animalcare.co.uk
Tom graduated from the Royal Veterinary College (RVC) in 2017 and joined Synergy Farm Health full-time in 2018, after completing his postgraduate diploma (PGDipVCP) with the RVC.
Nominated by his practice, Tom is described as a fine example of a dedicated caring professional who is passionate about sustainability, has a keen sense of his clients’ needs, and has developed strong working relationships with the farms under his care.
The judging panel found that Tom uses data effectively in herd health planning to highlight areas of improvement, working in partnership with his clients to promote disease prevention and profitability.
Tom’s clients spoke of his knowledge and caring attitude and how much he is valued as part of their team.
Tom said: “It was a privilege to be a part of the awards and to see farmers and businesses acknowledged - farmers don’t always get the recognition they deserve and seeing British dairying showcased was amazing.
"I hope winning is reward for the time and effort colleagues at Synergy put into young vets too, and that I can put it to good use supporting clients and working with other organisations within the dairy industry.
"My aim as a vet has been simply to support clients the best I could, both clinically and emotionally, so to have won made it a fantastic night and one I won’t be forgetting!”
The runner up as Charlie Mays of LLM Vets, who the judging panel praised for making effective changes on farm towards preventive healthcare and using data to assist with health and profitability.
Charlie also lobbies government to support the interests of the farmer and the industry.
Sabrina Jordan from Virbac said: ‘Virbac has been supporting dairy vets with products and services for over 50 years and recognise the commitment of young dairy vets to the profession.
"The standard of nominations into this category was outstanding, and our winner and highly commended nominees are a true credit to the veterinary profession, both are shining lights of the future’.
The British Safety Council has launched a new qualification to help people who drive as part of their work stay safe on the roads.
According to the organisation, the Level 2 Award in Safe Driving at Work provides work drivers with key knowledge of the hazards and risks associated with driving and equips them with valuable guidance on the measures available for reducing these risks, such as vehicle inspection, behaviour and defensive driving.
According to estimates from the Health and Safety Executive (HSE), up to a third of all road traffic accidents in Britain involve someone involved in work-related activity. In 2013, according to government figures, 1,713 people died on the road, with the total number of casualties standing at 183,670.
The Ofqual-regulated qualification, which is designed to be delivered by employers or training organisations, instructs learners on a range of topics including the particular risks associated with vulnerable road users, such as cyclists and pedestrians, the importance of regular vehicle safety checks and how to adapt driving style in response to changes in driving conditions or the actions of others.
Alex Botha, the British Safety Council's Chief Executive, said: "Driving can be a risky activity, a fact borne out by the high number of injuries and fatalities that occur annually on our roads.
"However, simple steps can be taken by employers and drivers to manage and reduce this risk. Our new Level 2 Award in Safe Driving at Work provides learners with all the essential knowledge to help them stay safe on the roads.
"Learners can expect to leave the qualification with a thorough knowledge of the main risks posed by driving - whether to themselves or other road users - and how to reduce them.
"Once registered with us, employers or training centres deliver the training using the high-quality teaching and student materials provided. Qualifications are assessed through a 45-minute multiple-choice examination that can be either taken online or on paper.
"This is a stand-alone qualification designed for delivery as a short course. It is also well-suited for integration into wider vocational programmes of study or, for example, as part of an induction programme. Students need no former knowledge or experience, so can come from a diverse range of educational and employment backgrounds.
"Safer driving habits should also feed through into workers' personal lives, providing employers with a valuable corporate social responsibility tool to help make our roads safer in and out of work."
Zoetis has announced that the European Commission has granted marketing authorization for Simparica™ (sarolaner) chewable tablets, a once-monthly medication for the treatment of fleas, ticks and sarcoptic mange in dogs beginning at eight weeks of age.
Dr. Balázs Capári, a Hungarian veterinary specialist in small animal medicine who participated in clinical trials of Simparica said: "The approval of Simparica gives veterinarians a new oral choice in parasite control for dogs. In my experience, Simparica has been shown to rapidly kill fleas and ticks with efficacy that persists for five weeks. Dog owners participating in the trials also reported that Simparica is very palatable; the chewable tablet was easily taken by their dogs. The convenience of a once monthly chewable tablet helps increase compliance with treatment, giving veterinarians and dog owners confidence in continuous protection."
Dr. Catherine Knupp, Executive Vice President and President, Research and Development at Zoetis, said: "At Zoetis, we focus our innovation on the most pressing needs of veterinarians, and that is what guided us to develop a new oral choice to provide dogs with persistent protection from fleas and ticks and treatment of mites that cause sarcoptic mange. Simparica is a result of the collaboration of Zoetis scientists worldwide, who share a determination to develop new medicines that deliver real value to our veterinary customers and the animals in their care. We are excited to bring this innovative medicine, Simparica, to veterinarians and dog owners across Europe."
The active substance of Simparica is sarolaner, a new ectoparasiticide in the isoxazoline class, developed by Zoetis.
Zoetis says the marketing authorization for Simparica was based on the results of field studies conducted in seven countries, involving more than 800 dogs of various breeds from at least eight weeks of age and 1.3 kg of weight. Simparica was shown to provide efficacy for at least five weeks against ticks and fleas. It demonstrated a rapid onset of action, killing fleas before they have a chance to lay eggs and can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis. It proved effective in treating sarcoptic mange, a highly contagious skin disease in dogs.
In studies, Simparica killed all four species of tick dominant in Europe (Dermacentor reticulatus, Ixodes hexagonus, Ixodes ricinus and Rhipicephalus sanguineus) and species of flea that most frequently infect dogs in European countries (Ctenocephalides felis and Ctenocephalides canis). Simparica was well tolerated with no adverse events reported at the therapeutic dose.
Zoetis expects to launch Simparica in the EU in the first quarter of 2016. Simparica chewable tablets will be available in 5mg, 10mg, 20mg, 40mg and 80mg dosage strengths.
For more information about Simparica and full prescribing information, visit http://www.zoetis.com/products-services/companion-animals/dogs.
Kit, who has served on Council as an elected member since 2013, is currently the Chair of the RCVS Finances & Resources Committee and has been RCVS Treasurer for the past three years.
He is also a member of a range of committees and project groups across the RCVS including: the Audit and Risk Committee; the PIC/ DC Liaison Committee; the Certification Subcommittee; the Estate Strategy Project Board; the RCVS Knowledge Board of Trustees; and the Advanced Practitioners Panel.
Since 2003 Kit has been working as an internist (he is an RCVS-recognised Specialist in Small Animal Medicine) in private referral practice. In 2006 he became a founding partner in a multidisciplinary referral centre that he saw grow from five to 65 members of staff within five years.
His interests include workforce issues, communicating the diverse clinical and non-clinical skills of veterinary surgeons to the general public and government, and facilitating life-long learning through achievable further professional qualifications and effective CPD.
Kit said: "It was a great honour to be elected as the next Junior Vice President by my fellow council members. I feel that I can make a positive contribution to the work that the RCVS is already undertaking in ensuring the veterinary team remains healthy and respected. In particular I am keen to look at how the RCVS can help find solutions to our workforce issues - improving retention as well as encouraging and facilitating vets and nurses back into the profession."
In addition to Kit being elected as JVP, the current holder of that office, Dr Mandisa Greene, was confirmed as President for 2020-21 and current President, Dr Niall Connell, was confirmed as Senior Vice-President for this period.
Professor Susan Dawson was voted in as RCVS Treasurer, and she will be formally invested in this role at Royal College Day on Friday, 10 July.
Professor David Argyle has been elected as Chair of Advancement of the Professions Committee for a second year, Dr Susan Paterson has been elected as Chair of Education Committee for her second year, and Dr Melissa Donald has been elected Chair of Standards Committee for her second year.
Kit and Melissa's positions are subject to their successful re-election in the 2020 RCVS Council Elections
More information on the RCVS Council and its members can be found on the RCVS website: https://www.rcvs.org.uk/who-we-are/rcvs-council.
Preliminary results, which recorded a decline in the quantities of antimicrobials prescribed from 2014 to 2018, were published in 2022.
A further audit has now been undertaken in all 22 of the company's first opinion practices to investigate the age, breed and estimated weight of each horse, the clinical indication for antibiotic use, the drugs prescribed, their dose rates, the route of administration and whether culture and sensitivity were used to guide antimicrobial selection.
Data collection was completed in August 2022.
This secondary audit was conducted using a ‘point prevalence’ survey, in which each CVS Equine first opinion Quality Improvement Lead gathered information about all systemic antibiotics prescribed by each of their practices on one day a month for 12 consecutive months.
The project yielded information on 331 cases where systemic antimicrobials were prescribed.
Complete data about the first line-drug selection were available for 261 prescriptions.
The commonest prescribed antimicrobial was sulfadiazine/trimethoprim (41%), followed by oxytetracycline (23%), procaine penicillin (16%), doxycycline (13%), gentamicin (4%), metronidazole (1%), ceftiofur (1%) and enrofloxacin (1%).
Highest priority critically important antimicrobials (ceftiofur and enrofloxacin) were only prescribed in four horses (clinical indications for these included possible sepsis, skin infection, lower respiratory tract infection and a wound complication – in none of these cases was the first-line drug selection based on the results of culture and sensitivity.
Overall, the clinical indications for antimicrobial use were recorded in 246 cases; the commonest indications were cellulitis/lymphangitis (27%), uncomplicated wounds (19%), surgical prophylaxis (15%), respiratory infections (11%) and skin infections (8%).
Hattie Lawrence, Director of CVS Equine, said: “Though the impact of this work is yet to be documented, there is anecdotal evidence that it has raised awareness amongst our veterinarians of the importance of antimicrobial stewardship.
"Taken together, the results of both pieces of work will be used to help develop and inform clinical audits and clinical guidelines of antimicrobial use in horses.”
Vita Referrals has been set up by Rob Quinn, an RCVS and EBVS Specialist in Small Animal Surgery, and Nick Blackburn and Stuart Cooke, both RCVS Advanced Practitioners in Small Animal Surgery.
They say that their aim is to ensure every pet owner has access to reasonably priced surgical care.
To that end, the clinic lists fixed costs for all of its major surgical specialities on its website, where it says clients should notice a significant reduction compared to other providers.
It also offers a 12-month post-surgical complications warranty.
Rob said: “Many pet-owners are unaware that there are three major companies which own the vast majority of veterinary practices in the UK.
"That is not necessarily of benefit to those using the services, as prices can rise when competition is low.
"Myself, Nick and Stuart felt very strongly that there was a different way to do things.
“No one becomes a vet to see animals suffer or pet-owners struggle to make tough financial decisions.
"We knew it was possible to offer a top quality service, with the best facilities and equipment available, whilst also keeping prices at a realistic level – and that is where the vision for Vita Referrals came from.
"We also wanted the freedom to offer collaborative decision-making, the removal of complex forms and bureaucracy and what we believe is an industry-leading 12-month complications guarantee on routine surgeries.
"It’s time there was more disruption and competition in the sector – and that will, ultimately, only be a good thing for pets, owners and vets.”
www.vitareferrals.co.uk
The Smart Home Monitoring Kit for pets includes an indoor camera which comes with an in-built temperature sensor and night vision, a door sensor and a Smart Plug which can be remotely activated to turn on a radio, lamp, portable heater or fan to help keep animals content.
Although designed primarily for pet owners, Petplan says the kit is also being used by some veterinary practices to help provide additional security and monitoring capabilities within the practice.
The kit also contains an SD card allowing clients to share footage of their pet in the home with their veterinary surgeon when explaining behavioural symptoms. Likewise the practice will be able to record and share footage with their staff or clients.
Isabella Von Mesterhazy, Head of Marketing at Petplan, said: "For Petplan, keeping pets healthy always has been and always will be our priority. Spending time away from your pet can be hard, so the new pet Monitoring Kit addresses this problem by providing welcome peace of mind that they are safe and well. We are delighted to be able to offer Petplan veterinary practices and their staff the chance to get their hands on a Monitoring Kit at an exclusive price."
To find out more about the exclusive offer available for Petplan veterinary practices and staff until 9th December, visit petplanvet.co.uk.
The RCVS Disciplinary Committee has dismissed a case against a London-based veterinary surgeon, having found charges related to fraudulent registration not proved.
Miss Maria Becerra Parga was charged with fraudulently entering her name on the Register of Veterinary Surgeons, by submitting a registration application in 2005 that contained a forged certificate of good standing from the Distinguished Official Veterinary Association of Lugo, Spain.
The Committee said that, in order to conclude Miss Becerra Parga had acted dishonestly, it needed to be sure that when she submitted the certificate to the RCVS she knew it was not genuine.
Miss Becerra Parga admitted that she did not make any application for the certificate directly to the Lugo Association. She accepted that the certificate she supplied to the College (the number of which was genuine and corresponded to a male veterinary surgeon registered in Spain) was a forgery, and that it contained a reference to her degree, a statement of good conduct, and was dated before she had a need for it; however, she said, this had been given to her by a friend and veterinary colleague and she had understood that she had been given a temporary membership of the Lugo Association for the purpose of registering with the RCVS. She also said that she had left these arrangements to her colleague and assumed that the document she had been given was genuine.
Her colleague, called as a witness by the College, said that Miss Becerra Parga had admitted the fraud to her and she denied that she had given the certificate to Miss Becerra Parga. Her friend said that she gave no more than general guidance because she knew that Miss Becerra Parga would be guided by a UK company that would arrange for her registration with the RCVS and through which she would be employed. She thought it possible that she had told Ms Becerra Parga that she needed a letter of recommendation, but she was not sure.
After careful consideration, the Committee preferred the evidence of Miss Becerra Parga and found her account to be "consistent with her naivety, inexperience and trusting nature" and "was sure that she did not forge the document herself". It found that to the extent that Miss Becerra Parga read the certificate at all when given it, she obviously did not notice its date or significance. The Committee was not able to say who was responsible for forging the certificate.
The Committee also dismissed an argument RCVS Counsel put forward, that Miss Becerra Parga had neither offered nor made payment for the certificate, and that she had forged the certificate to avoid a payment. The Committee said it did not find it credible that a veterinary surgeon, in work with a supportive family, who obviously was easily able to obtain proof of her good character directly from the university if necessary, would have jeopardised her entire career by forging the document, let alone for a small financial advantage.
The Committee directed that the charges be dismissed.
Bimeda has announced the launch of Butagran Equi (phenylbutazone), to join its range of analgesics and anti-inflammatories.
Bimeda says that Butagran Equi provides rapid onset of activity with the added convenience for horse owners or professionals of being presented as an easy-to-administer sweetened powder.
Indications include musculo-skeletal conditions that require relief from pain and a reduction in the associated inflammation, including lameness associated with osteoarthritic conditions, bursitis, laminitis and soft tissue inflammation.
Head of Bimeda technical services Padraig Hyland MVB said: "Butagran Equi is particularly suited where continued mobility is considered desirable. It is also of value in limiting post-surgical inflammation, myositis and other soft tissue inflammation and can be used as an anti-pyretic where this is considered advisable, such as in viral respiratory infections. And being a sweetened powder it's quite straightforward for horse owners to administer and dose as prescribed."
He added: "Butagran Equi follows the launch of a number of new products and is proof our desire to provide a comprehensive and relevant equine portfolio backed up with first class technical support."
Equine vets at the Animal Health Trust are appealing to horse riders to help with a research project, to assess the interaction between horse, saddle and rider.
Dr Sue Dyson, Head of Clinical Orthopaedics at the Centre for Equine Studies at the Animal Health Trust and Line Greve, PhD student, are conducting the study to find out how the horse, rider and saddle can influence each other. They are trying to understand better why a saddle may persistently slip to one side in some horses.
Line said: "Saddle slip is a problem seen in all sorts of horses and ponies and can contribute to back pain and thus impaired performance. Research suggests that 25% of British dressage horses have a history of back-related problems and subsequent reduced performance. Our preliminary studies involve just over 700 riders but for a more accurate picture we would like to bump this figure up to 1000 plus. We are urging all riders, whatever their level or ability, to help by completing the questionnaire."
The online questionnaire should take no more than 15 minutes to complete and all answers remain anonymous. The questions cover saddle types, fitting, use and maintenance; rider experience, training and 'handedness'; as well as horse type, use and any previous lameness or back-related problems.
To take part in the study, complete the questionnaire here: http://www.aht.org.uk/cms-display/premise_questionnaire.html. The AHT says that by doing so, you'll be helping to protect and improve the future health, welfare and longevity of the ridden horse.
The results will be presented at the Saddle Research Trust Conference in 2014.